Pro Medicus has reported record FY 2026 results, with revenue increasing to AUD 261.7 million and underlying EBIT reaching AUD 196 million. The company's shares rose 12.4% to $197.67 in pre-market trading. Pro Medicus's core business remains concentrated in North America, accounting for over 90% of revenue. The company serves 11 of the top 20 U.S. News Best Hospitals and has a 100% retention record.
Revenue Growth
Revenue growth exceeded 30% in constant currency, despite foreign-exchange pressure. The company expects FY 2027 to be bigger than FY 2026, with constant-currency revenue and EBIT growth targeted at more than 30%.
New Product Launches
Pro Medicus is set to launch new products, including Visage 7 and digital pathology, in early calendar 2027. The company's reporting product is expected to add 30% to 35% in revenue per exam if adopted broadly.